NCT06159478View on ClinicalTrials.gov

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

February 28, 2027

Study Completion Date

September 30, 2027

Conditions
Low-grade GliomaPancreatic Cancer
Interventions
DRUG

Binimetinib 15 MG

Binimetinib 45mg is orally administered twice daily.

Trial Locations (6)

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

060-8648

RECRUITING

Hokkaido University Hospital, Sapporo

606-8507

RECRUITING

Kyoto University Hospital, Kyoto

980-8574

RECRUITING

Tohoku university Hospital, Sendai

104-0045

RECRUITING

National Cancer Center Japan, Chuo-ku

812-8582

RECRUITING

Kyushu University Hospital, Fukuoka

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

National Cancer Center, Japan

OTHER_GOV